Neoadjuvant Immunotherapy clinical trials

Explore recruiting neoadjuvant immunotherapy clinical trials.

Recruiting neoadjuvant immunotherapy studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Neoadjuvant Immunotherapy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Towards organ preservation and cure via immunotherapy in cutaneous squamous cell carcinoma patients, normally undergoing extensive curative surgery and radiotherapy: Matisse-2

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase II trial exploring combined neoadjuvant therapy with Pembrolizumab/Lenvatinib and adjuvant Pembrolizumab in patients with surgically resectable Non-Small- Cell Lung Cancer (NSCLC)

Austria

Therapeutic exploratory (Phase II) EU CTIS Study details

Neoadjuvant Triple Treatment with mFOLFIRINOX, pembrolizumab and SABR in patients with (borderline) resectable pancreatic cancer (PREOPANC-5): a multicenter single arm phase Ib/II trial of the Dutch Pancreatic Cancer Group

Netherlands

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Immune-modulatory radiotherapy to enhance the effects of neoadjuvant PD-L1 blockade after neoadjuvant chemotherapy in patients with resectable stage III(N2) non-small cell lung cancer (NSCLC). A multicenter phase II trial.

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Neoadjuvant immune checkpoint inhibition and novel IO combinations in early-stage colon cancer - the NICHE trial

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A PHASE IB/II, OPEN-LABEL, MULTICENTER, RANDOMIZED PLATFORM STUDY EVALUATING THE EFFICACY AND SAFETY OF NEOADJUVANT IMMUNOTHERAPY COMBINATIONS IN PATIENTS WITH SURGICALLY RESECTABLE HEPATOCEULLULAR CARCINOMA (MORPHEUS-NEO HCC)

Austria, Spain, Germany, France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Neoadjuvant Immunotherapy trials by city

Neoadjuvant Immunotherapy in Toronto Neoadjuvant Immunotherapy in Vancouver Neoadjuvant Immunotherapy in Montreal Neoadjuvant Immunotherapy in Calgary Neoadjuvant Immunotherapy in Edmonton Neoadjuvant Immunotherapy in Ottawa Neoadjuvant Immunotherapy in Winnipeg Neoadjuvant Immunotherapy in Quebec City Neoadjuvant Immunotherapy in Hamilton Neoadjuvant Immunotherapy in Kitchener Neoadjuvant Immunotherapy in London Neoadjuvant Immunotherapy in Halifax Neoadjuvant Immunotherapy in New York Neoadjuvant Immunotherapy in Los Angeles Neoadjuvant Immunotherapy in Chicago Neoadjuvant Immunotherapy in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease